Elsevier

Life Sciences

Volume 66, Issue 8, 14 January 2000, Pages 745-753
Life Sciences

Treatment and survival study in the C57BL/6J-APCMin/+ (Min) mouse with R-flurbiprofen

https://doi.org/10.1016/S0024-3205(99)00645-1Get rights and content

Abstract

Our previous studies with the mouse model of familial adenomatous polyposis (FAP), C57BL/6J-APCMin/+ or Min mouse, demonstrated the optimal dose for adenoma reduction with R-flurbiprofen was 10 mg/kg/day as an undivided dose. Divided doses exhibited no increased efficaciousness. This study examines 10 mg/kg R-flurbiprofen daily (qd) on survival as well as a second daily (q.o.d.) schedule and compares it with sulindac sulfone. The q.o.d. Schedule at 10 mg/kg was equally efficacious as qd treatment at the same dose. For the q.o.d. Group, tumor number decreased similarly (p < 0.01); while body weight gain (p < 0.01), hematocrit and average tumor area (both, p < 0.05) were improved compared with qd treatment. Treatment with R-flurbiprofen (10 mg/kg/day) increased survival significantly (p = 0.0004, log-rank) compared to vehicle treated animals. Major biological endpoints (hematocrit, weight gain, tumor number, average and total area[99% reduction]) were significantly improved in treated animals (p < 0.01). Sulindac sulfone treatment (50 mg/kg/day) of the Min mouse produced no significant biological benefit. The dose schedule study suggests that for tumor reduction it is necessary to attain a threshold drug-level but not necessarily sustain it over 24 hrs (pharmacodynamic t1/2 ⪢ pharmacokinetic t1/2). During the period of administration R-flurbiprofen dramatically prolongs survival for the mouse model of the human disease, FAP.

References (29)

  • J. Groden et al.

    Cell

    (1991)
  • S. Katusic et al.

    Am. J. Med.

    (1985)
  • E.R. Fearon et al.

    Cell

    (1990)
  • M.J. Thun et al.

    N. Engl. J. Med.

    (1991)
  • O. Suh et al.

    Cancer

    (1993)
  • A. Paganini-Hill et al.

    Brit. Med. J.

    (1989)
  • E. Giovannucci et al.

    N. Engl. J. Med.

    (1995)
  • D. Labayle et al.

    Gastroenterology

    (1995)
  • F.M. Giardiello et al.

    N. Engl. J. Med.

    (1993)
  • J. Rigau et al.

    Ann. Intern. Med.

    (1991)
  • R.F. Jacoby et al.

    Cancer Research

    (1996)
  • B.S. Reddy et al.

    Cancer Res.

    (1987)
  • L.J. Marnett

    Cancer Res.

    (1992)
  • M. Sato et al.

    J. Cancer Res. Clin. Oncol.

    (1993)
  • Cited by (57)

    • Zn(II) complexes of (E)-4-(2-(pyridin-2-ylmethylene)hydrazinyl)quinazoline in combination with non-steroidal anti-inflammatory drug sodium diclofenac: Structure, DNA binding and photo-cleavage studies, antioxidant activity and interaction with albumin

      2020, Journal of Inorganic Biochemistry
      Citation Excerpt :

      A combination of L and Zn with another ligand such as the widespread commercially available non-steroidal anti-inflammatory drug (NSAID) sodium diclofenac (Nadicl) (Fig. 1(B)) has also been designed. Nadicl is used as analgesic, antipyretic and anti-inflammatory agent [39]. In addition, Nadicl is proposed for the treatment of rheumatoid arthritis and osteoarthritis [40,41].

    View all citing articles on Scopus
    View full text